Seno Medical Instruments, Inc. Elects Leading Radiologist to Scientific Advisory Committee
February 07, 2008
×
SENO Medical Instruments Announces Receipt of $1 Million from the TETF
January 08, 2008
×
Seno Medical Instruments, Inc. Presents at the San Antonio Breast Cancer Symposium
December 20, 2007
SAN ANTONIO, TEXAS-December 21, 2007-Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices held a reception at La Villita Arts Village to honor leadership and program participants of the 30th annual San Antonio Breast Cancer Symposium (SABCS).
The SABCS provided state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers. Last year the attendees numbered over 9000 and represented 83 countries.
“As one out of every two deaths in women in the U.S. is due to breast cancer, Seno is excited to be part of the SABCS community as we continue in making advancements in conquering cancer”, said Janet Campbell, Seno Medical CEO. “Seno is honored to host a number of distinguished guests and physicians from across the world during the symposium”.
As part of the SABCS program, Seno presented two poster sessions on its patented opto-acoustic technology: “Initial Clinical Evaluation of Laser Opto-acoustic Imaging System for Diagnostic Imaging of Breast Cancer” and “Molecular Imaging in the Mouse Model of Breast Cancer based on Optical Illumination & Ultrasonic Detection”
During the conference, Seno announced the introduction of its Imagio™ research device, a new platform technology using opto-acoustics for small animal functional imaging. Seno’s break through technology was recognized by the State of Texas in August when the company received a $2 million investment by the Texas Emerging Technology Fund.
At Seno’s reception, guests had the pleasure of listening to a number of distinguished speakers. Speakers included Dr. Robert Kramer, founding member of the Susan G. Komen Advisory Board and a member of the Seno Scientific Advisory Committee as well as State Representative Joe Straus who represents the San Antonio community in the Texas Legislature.
Representative Straus said, “Seno’s breakthrough technology promises breast cancer patients will be able to receive better diagnosis and treatment. The State of Texas is pleased to be its partner.”
×
Seno Medical Instruments, Inc. Launches Imagio™ Research Device
September 06, 2007
×
SENO Medical Instruments Announces $2 Million State Investment for Breast Cancer Detection Technology
August 20, 2007
SAN ANTONIO, TEXAS — August 21, 2007 – Seno Medical Instruments, Inc., a company engaged in the development of medical devices announced a $2 million dollar award from the Texas Emerging Technology Fund (TETF). This funding will allow the company to further develop its life saving technology for cancer imaging and detection and move it closer to the global marketplace.
Texas Secretary of State Phil Wilson and Seno Medical Instruments, Inc. CEO Janet Campbell announced the Fund’s investment during a joint press conference at the world renowned Cancer Therapy and Research Center in San Antonio. The patented functional imaging technology will be commercialized to produce real-time color images which differentiate benign and malignant tumors, for all solid tumors, such as in breast cancer. Seno’s intent is to provide the most advanced high quality products for cancer screening, diagnosis and therapeutic treatment that are more humane than existing technologies.
“I am pleased that the state of Texas and its elected leadership recognize and support Seno’s technology, and our effort to create better tools for the detection and treatment of breast cancer. On behalf of my management team, we are grateful for the support we’ve received from our investors and organizations, not only in our hometown of San Antonio, but across Texas and the nation,” said Campbell.
The TETF is a $200 million program created by the Texas Legislature in 2005. A 17-member advisory committee of high-tech leaders, entrepreneurs and research experts reviews potential TETF projects and recommends funding for projects to the Governor, Lieutenant Governor and Speaker of the House. To date, the TETF has allocated $94.1 million in grant funds to Texas companies and universities across the state.
“Technological innovation is the lifeblood of today’s economy,” said Texas Governor Rick Perry. “Texas is making an important investment, literally, in the foundation of our future. By supporting advancing technology projects, such as breast cancer diagnostic devices, we are making a difference in a wide variety of products and services that enhance the quality of lives here today, and in the future.”
Seno Medical has selected the Cancer Therapy and Research Center and the University of Texas Health Science Center at San Antonio to conduct initial clinical studies.
×
Seno Medical Instruments, Inc. Elects Former Head of FDA to Scientific Advisory Board
July 12, 2007
SAN ANTONIO, TEXAS—July 13, 2007—Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the appointment of Lester Crawford, Ph.D., D.V.M. to its Scientific Advisory Committee. Dr. Crawford, widely known for his experience as Deputy Commissioner and Commissioner at the Food and Drug Administration between 2002 and 2005, joins a prestigious group of professionals dedicated to the early detection of cancer.
Seno Medical Instruments, Inc. was formed in 2005 to commercialize a new modality in cancer screening and diagnosis: laser opto-acoustic imaging. To further the development of this potentially life-saving technology, the company is assembling a team of experts in the field of breast cancer detection, product application and protocol design. Dr. Crawford joins Robert L. Kramer, M.D., founding member of the Susan G. Komen Advisory Board and Charles Coltman, M.D., President Emeritus of San Antonio’s Cancer Therapy and Research Center on the committee. Also on Seno Medical’s Scientific Advisory Committee is John W. Holaday, Ph.D., formerly listed among the 500 most cited scientists in the world by the Science Citation Index.
“We are delighted that Dr. Crawford has agreed to join our Scientific Advisory Committee. As a recognized leader of a national organization such as the FDA, we are confident he will bring a wealth of knowledge and experience to the committee and to the company,” said Janet Campbell, Seno Medical CEO.
Dr. Crawford has played major roles in mandatory nutrition labeling, the formation of the World Trade Organization and the control of chemical and microbiological contaminants of food. He has been an advisor to the World Health Organization of the United Nations for much of his career. Previously Chair of Department of Physiology-Pharmacology at the University of Georgia, Dr. Crawford has also been Administrator of the Food Safety and Inspection Service (USDA) and Director of the Center for Food and Nutrition Policy from 1997 to 2002, first at Georgetown University and at Virginia Tech, where it moved in 2001. He is a member of the National Academy of Sciences Institute of Medicine, a Fellow of the Royal Society of Medicine (UK) and a Fellow of the International Society of Food Science and Technology.
×